Stocks · News reference
B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share
Filed: 2026-08-10 AccNo: 0001193125-26-342371 Size: 541 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025Seminal Study Successfully Achieved Primary and Secondary Endpoints,